Cargando…
Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizzines...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Formosan Medical Association. Published by Elsevier Taiwan LLC.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375841/ https://www.ncbi.nlm.nih.gov/pubmed/35977867 http://dx.doi.org/10.1016/j.jfma.2022.07.009 |
_version_ | 1784768042284089344 |
---|---|
author | Sheng, Wang-Huei Wang, Chung-Cheng Chu, Ching-Chi Lin, Yueh-Juh Chang, Sui-Yuan Ieong, Si-Man Chang, Shan-Chwen |
author_facet | Sheng, Wang-Huei Wang, Chung-Cheng Chu, Ching-Chi Lin, Yueh-Juh Chang, Sui-Yuan Ieong, Si-Man Chang, Shan-Chwen |
author_sort | Sheng, Wang-Huei |
collection | PubMed |
description | We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation. |
format | Online Article Text |
id | pubmed-9375841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Formosan Medical Association. Published by Elsevier Taiwan LLC. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93758412022-08-15 Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan Sheng, Wang-Huei Wang, Chung-Cheng Chu, Ching-Chi Lin, Yueh-Juh Chang, Sui-Yuan Ieong, Si-Man Chang, Shan-Chwen J Formos Med Assoc Short Communication We reported 25 recipients (14 females and 11 males) aged from 18 to 65 years who unexpectedly received a primary dose of undiluted BNT162b2 vaccine (180 μg). The most common adverse reactions included injection site pain (n = 22), followed by fever (9), fatigue (8), chest tightness (6), and dizziness (6). The most common laboratory abnormalities were anemia (n = 4) and elevated liver transaminase level (4), followed by abnormal leukocyte counts (3) and elevated D-dimer level (3). The adverse reactions and laboratory abnormalities of these recipients were mild and spontaneously recovered within a few weeks. Significant elevations of anti-SARS-CoV-2 spike IgG titers after a booster dose of the BNT162b2 were found. Similar to reports of BNT162b2 clinical trials, the adverse reactions and laboratory abnormalities of these recipients were mild, and they spontaneously recovered within a few weeks. These results provide clinical and immunological effects of undiluted BNT162b2 vaccine inoculation. Formosan Medical Association. Published by Elsevier Taiwan LLC. 2023-01 2022-08-14 /pmc/articles/PMC9375841/ /pubmed/35977867 http://dx.doi.org/10.1016/j.jfma.2022.07.009 Text en © 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Sheng, Wang-Huei Wang, Chung-Cheng Chu, Ching-Chi Lin, Yueh-Juh Chang, Sui-Yuan Ieong, Si-Man Chang, Shan-Chwen Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title | Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title_full | Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title_fullStr | Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title_full_unstemmed | Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title_short | Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan |
title_sort | safety and antibody response of recipients who unexpectedly received undiluted prime dose of bnt162b2 covid-19 vaccine in taiwan |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375841/ https://www.ncbi.nlm.nih.gov/pubmed/35977867 http://dx.doi.org/10.1016/j.jfma.2022.07.009 |
work_keys_str_mv | AT shengwanghuei safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT wangchungcheng safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT chuchingchi safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT linyuehjuh safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT changsuiyuan safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT ieongsiman safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan AT changshanchwen safetyandantibodyresponseofrecipientswhounexpectedlyreceivedundilutedprimedoseofbnt162b2covid19vaccineintaiwan |